AstraZeneca plc (LON:AZN) has decided to discontinue the STABILIZE-CKD and DIALIZE-Outcomes Phase III evidence trials for Lokelma (sodium zirconium cyclosilicate). The decision was made due to substantially increased enrolment timelines..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 31.9% according to Barclays.Barclays set a target price of 13,500 GBX for the company, which when compared to the..
AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the US for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast..
AstraZeneca plc (LON:AZN) has announced its 9M and Q3 2023 results. Revenue and EPS summary 9M 2023 Q3 2023 % Change % Change $m Actual CER[1] $m Actual ..
AstraZeneca plc (LON:AZN) and Eccogene have entered into an exclusive licence agreement for ECC5004, an investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) for the treatment of obesity, type-2..
AstraZeneca plc (LON:AZN) has announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet need,..
AstraZeneca plc (LON:AZN) has entered into settlement agreements in the product liability litigations related to Nexium and Prilosec. The agreements effectively resolve the product liability claims that are currently pending..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 22.2% according to Barclays.Barclays set a target price of 13,500 GBX for the company, which when compared to the..
AstraZeneca PLC (LON:AZN) has announced that positive high-level results from the TROPION-Breast01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement for the primary..
AstraZeneca plc (LON:AZN) Alexion, AstraZeneca Rare Disease, has completed a definitive purchase and licence agreement for a portfolio of preclinical rare disease gene therapy programmes and enabling technologies from Pfizer..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 3.6% according to Deutsche.Deutsche set a target price of 11,000 GBX for the company, which when compared to the..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 27.2% according to Barclays.Barclays set a target price of 13,500 GBX for the company, which when compared to the..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 3.8% according to Deutsche.Deutsche set a target price of 11,000 GBX for the company, which when compared to the..
AstraZeneca plc (LON:AZN) Alexion has announced that it has entered a definitive purchase and licence agreement for a portfolio of preclinical gene therapy programmes and enabling technologies from Pfizer Inc...
AstraZeneca plc (LON:AZN) has announced datopotamab deruxtecan met dual primary endpoint of progression-free survival in patients with advanced non-small cell lung cancer in TROPION-Lung01 Phase III trial. Positive high-level results..
The US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) has voted unanimously 21 to 0 that AstraZeneca and Sanofi’s nirsevimab has a favourable benefit risk profile for..
AstraZeneca plc (LON:AZN) Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy. Positive high-level results from the DUO-E Phase III..
AstraZeneca PLC (LON:AZN) has announced that Anna Manz has been appointed as a Non-Executive Director and a member of the Audit Committee with effect from 1 September 2023. Anna is..
Positive high-level results from the FLAURA2 Phase III trial showed AstraZeneca plc (LON:AZN) Tagrisso (osimertinib) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival..
AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. The approval..
